Research programme: next generation protein-based therapeutics - EQRx/Absci
Latest Information Update: 11 Mar 2024
Price :
$50 *
At a glance
- Originator AbSci; EQRx
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Immunological disorders